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The global escalation of obesity and diabetes in developed and
developing nations poses a great health challenge. Obesity
is one of the major causes of type 2 diabetes [1, 2]. Type
1 diabetes is primarily due to the autoimmune-mediated
destruction of pancreatic beta-cell leading to insulin defi-
ciency [3, 4]. This is usually accompanied by alterations in
lipid metabolism, enhanced hyperglycemia-mediated oxida-
tive stress, endothelial cell dysfunction, and apoptosis [3, 4].
Similarly, in type 2 diabetes, increased glucotoxicity, lipotox-
icity, endoplasmic reticulum-induced stress, and apoptosis
lead to the progressive loss of beta-cells [3, 4]. While type 1
diabetes is characterized by the presence of beta-cell autoan-
tibodies, a combination of peripheral insulin resistance and
dysfunctional insulin secretion by pancreatic beta-cells is
implicated in the pathogenesis of type 2 diabetes [3, 4].
Although insulin resistance has traditionally been associated
with type 2 diabetes, mounting evidence indicates that the
incidence of insulin resistance in type 1 diabetes is increasing
[5, 6]; therefore novel mechanistic approaches deciphering
insulin resistance are needed. Many pathophysiological fac-
tors are implicated in insulin resistance. Although the exact
nature of these factors is not completely understood, it is
becoming increasingly clear that oxidative stress, inflamma-
tion, genetic, habitual, environmental, and epigenetic factors
may be involved [7–14].
In the past decade, significant strides have been made
in elucidating important mechanisms associated with insulin
resistance, overt diabetes, and related cardiometabolic dis-
eases. However, more intense research is still needed for
more comprehensive understanding of the pathophysiolog-
ical profile of insulin resistance in diabetes, and especially
in situations where diabetes is comorbid with other chronic
diseases.
In this special issue research and review papers that
address a broad range of mechanisms associated with insulin
resistance, type 1 diabetes, type 2 diabetes, and related
cardiometabolic complications are discussed. Accordingly,
in a review article by X. Jiang et al. the impact of habitual
and environmental factors on the development of diabetes is
discussed. Particularly, X. Jiang et al. showed that nutritional,
environmental, and physiological factors at prenatal age are
correlated to the manifestation of insulin resistance and
type 2 diabetes in later stages of adult life. On the other
hand, healthy habits including exercise may prevent diabetes.
Accordingly, C.-H. Hunget al. wrote an article showing the
benefits of exercise on attenuating inflammation in diabetes
and related complications. To further elucidate the patho-
physiological role of inflammation on diabetes, Y. I. Sa´nchez-
Zamora and M. Rodriguez-Sosa wrote a review article on
the effects of macrophage migration inhibitory factor in type
1 and type 2 diabetes. In another related article, A. Zhu et
al. reviewed the effects of abdominal adiposity on diabetes,
while X. Zhang et al. reported the effects of fluctuating
glucose levels on carotid artery intima-media thickness and
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the development of coronary artery disease. Besides vascular
complications, many diabetic patients have increased risk of
thrombosis due to insulin resistance and elevated inflamma-
tion [15]. This notion was further investigated in an article
featuring in this special issue written by I. Isordia-Salas et al.
Among the major microvascular complications in dia-
betes are diabetic retinopathy and diabetic nephropathy. To
shed more lights on these diabetic complications, X. Li et al.
investigated the effects of oxidative stress on retinal neuron
apoptosis, while G. Wu et al. reported the renoprotective
effects of benidipine in streptozotocin-induced diabetic rats.
Taken together, the articles featuring in this special issue
cover a broad range of themes of considerable interest and
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